OncoMatch/Clinical Trials/NCT06565247
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Is NCT06565247 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including [18F]PSMA-PET and MRI sequences optimized for prostate cancer examinations for prostate cancer.
Treatment: [18F]PSMA-PET · MRI sequences optimized for prostate cancer examinations — In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
WHO 0–1
Prior therapy
Cannot have received: antiandrogen
Patients treated with neoadjuvant/concomitant anti-testosterone treatment (surgical or medical castration or anti-androgens)
Cannot have received: transurethral resection of the prostate
TUR-P within 6 months
Lab requirements
Kidney function
Creatinine clearance < 30ml/min [excluded]
Creatinine clearance < 30ml/min (acc. to http://www.fass.se/LIF/produktfakta-/kreatinin.jsp)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify